Matches in Nanopublications for { ?s ?p "[Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_assertion description "[Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP862697.RAnLyL4KnuUJ-UxA_4xc4jGNfCQTpsbFu7VkIJ3qnB7eA130_provenance.
- assertion description "[Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_assertion description "[Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP996473.RAQsGBZFbJ9Kwn9HUo0tn6B6Ez5TDr0Y3YOV2F2Kx0lG0130_provenance.
- NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_assertion description "[Overall, our data provide convincing evidence to suggest that pharmacologic inhibition of FGFR1 fusion kinases with ponatinib is likely to be beneficial for patients with SCLL and perhaps for other human disorders associated with dysregulated FGFR1 activity.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP400764.RAKi7HPAWw2mxXXu5FAAiFXcDoh7KC7m53JLF0dsdt0Cs130_provenance.